Source - SMW
ValiRx has provided an update on the clinical progress of an anti-cancer compound developed by ValiSeek, a joint venture between ValiRx and Tangent Reprofiling.

Data analysed by Ariana, a digital health company, showed that the VAL401 treatment had a measureable improvement on patient quality of Life, in addition to a positive impact on the disease, ValiRx said.


At 8:27am: (LON:VAL) ValiRx PLC share price was +0.13p at 4.63p